Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases

被引:350
|
作者
Rieder, Florian [1 ,2 ,3 ]
Fiocchi, Claudio [1 ,2 ]
Rogler, Gerhard [4 ,5 ]
机构
[1] Digest Dis & Surg Inst, Dept Gastroenterol Hepatol & Nutr, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA
[4] Univ Zurich, Univ Hosp, Div Gastroenterol & Hepatol, Zurich, Switzerland
[5] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland
基金
美国国家卫生研究院; 瑞士国家科学基金会;
关键词
Crohn's Disease; Ulcerative Colitis; Dilation; Treatment; ENDOSCOPIC BALLOON DILATION; IDIOPATHIC PULMONARY-FIBROSIS; STRICTURING CROHNS-DISEASE; SIDE ISOPERISTALTIC STRICTUREPLASTY; MALIGNANT COLORECTAL STRICTURES; 4TH SCIENTIFIC WORKSHOP; TISSUE GROWTH-FACTOR; LONG-TERM OUTCOMES; INTESTINAL FIBROSIS; ANASTOMOTIC STRICTURES;
D O I
10.1053/j.gastro.2016.09.047
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the last 10 years, we have learned much about the pathogenesis, diagnosis, and management of intestinal fibrosis in patients with inflammatory bowel diseases. Just a decade ago, intestinal strictures were considered to be an inevitable consequence of long-term inflammation in patients who did not respond to anti-inflammatory therapies. Inflammatory bowel diseasesLassociated fibrosis was seen as an irreversible process that frequently led to intestinal obstructions requiring surgical intervention. This paradigm has changed rapidly, due to the antifibrotic approaches that may become available. We review the mechanisms and diagnosis of this serious complication of inflammatory bowel diseases, as well as factors that predict its progression and management strategies.
引用
收藏
页码:340 / +
页数:17
相关论文
共 50 条
  • [21] Medical treatment of inflammatory bowel diseases
    Van Assche, G
    Vermeire, S
    Rutgeerts, P
    CURRENT OPINION IN GASTROENTEROLOGY, 2005, 21 (04) : 443 - 447
  • [22] Phytochemicals for the treatment of inflammatory bowel diseases
    Mathias Jochen Schneider
    Heba Abdel-Aziz
    Thomas Efferth
    Phytochemistry Reviews, 2014, 13 : 629 - 642
  • [23] Nanomedicines for the treatment of inflammatory bowel diseases
    Ali, Hussain
    Collnot, Eva-Maria
    Windbergs, Maike
    Lehr, Claus-Michael
    EUROPEAN JOURNAL OF NANOMEDICINE, 2013, 5 (01) : 23 - 38
  • [24] Treatment Strategies in Inflammatory Bowel Diseases
    Stallmach, Andreas
    Atreya, Raja
    Grunert, Philip Christian
    Stallhofer, Johannes
    de Laffolie, Jan
    Schmidt, Carsten
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (45): : 768 - 778
  • [25] Treatment of chronic inflammatory bowel diseases
    Lemann, Marc
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2007, 191 (06): : 1125 - 1141
  • [26] Diet in Treatment of Inflammatory Bowel Diseases
    Sasson, Alexa N.
    Ananthakrishnan, Ashwin N.
    Raman, Maitreyi
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (03) : 425 - +
  • [27] Food as Treatment of Inflammatory Bowel Diseases
    Maldonado-Contreras, Ana
    INFECTION AND IMMUNITY, 2022, 90 (05)
  • [28] Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management
    Laredo, Viviana
    Garcia-Mateo, Sandra
    Martinez-Dominguez, Samuel J.
    de la Cruz, Julia Lopez
    Gargallo-Puyuelo, Carla J.
    Gomollon, Fernando
    CANCERS, 2023, 15 (03)
  • [29] Vaccination in Patients with Inflammatory Bowel Diseases
    Manser, Christine N.
    Maillard, Michel H.
    Rogler, Gerhard
    Schreiner, Philipp
    Rieder, Florian
    Buehler, Silja
    DIGESTION, 2020, 101 (SUPPL 1) : 58 - 68
  • [30] Inflammatory bowel diseases in COPD patients
    Berdyugina, Antonina
    Klester, Elena
    Klester, Karolina
    Elykomov, Valery
    Belova, Irina
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56